Molecular Templates (MTEM) Stock Price, News & Analysis

Company Overview

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 4.19 million shs
• Market Capitalization: $1,000.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Molecular Templates Stock Analysis - MarketRank™

Molecular Templates scored higher than 13% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Molecular Templates.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Molecular Templates is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Molecular Templates is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for MTEM.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Molecular Templates does not currently pay a dividend.

Dividend Growth

Molecular Templates does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -0.93

Short Interest

There is no current short interest data available for MTEM.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Molecular Templates this week, compared to 0 articles on an average week.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Molecular Templates insiders have not sold or bought any company stock.

Percentage Held by Insiders

13.90% of the stock of Molecular Templates is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

95.47% of the stock of Molecular Templates is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MTEM Stock Analysis - Frequently Asked Questions

How were Molecular Templates' earnings last quarter?

Molecular Templates, Inc. (NASDAQ:MTEM) announced its quarterly earnings results on Monday, November, 15th. The biotechnology company reported ($8.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.67) by $2.43. The biotechnology company had revenue of $2.38 million for the quarter, compared to analyst estimates of $15.69 million. Molecular Templates had a negative net margin of 61.35% and a negative trailing twelve-month return on equity of 260.50%.

When did Molecular Templates' stock split?

Shares of Molecular Templates reverse split on Monday, August 14th 2023. The 1-15 reverse split was announced on Friday, August 11th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 11th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of Molecular Templates?

Shares of MTEM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Molecular Templates own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Molecular Templates investors own include NVIDIA (NVDA), Meta Platforms (META), GE Aerospace (GE), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), Alibaba Group (BABA) and Catalyst Pharmaceuticals (CPRX).

Company Calendar

• Last Earnings: 11/15/2021
• Today: 4/26/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:MTEM
• CIK: 1183765
• Web: www.mtem.com
• Phone: (512) 869-1555
• Fax: 650-474-2529
• Employees: 260
• Year Founded: 2009

Profitability

• EPS (Most Recent Fiscal Year): ($2.70)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-8,120,000.00
• Net Margins: -61.35%
• Pretax Margin: -61.39%
• Return on Equity: -260.50%
• Return on Assets: -46.90%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.56
• Quick Ratio: 1.56

Sales & Book Value

• Annual Sales: $23.48 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.78 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 6,584,000
• Free Float: 5,669,000
• Market Cap: $1,000.00
• Optionable: No Data
• Beta: 1.53